Development

Latest News

Eye on Pharma banner
Eye on Pharma: New Data, Clinical Developments, and Biosimilar Partnerships

July 4th 2024

As Celltrion publishes phase 3 data on its tocilizumab biosimilar, other companies finalize partnerships, and Formycon begins development for a pembrolizumab biosimilar.

patient getting biosimilar injection | Image credit: terovesalainen - stock.adobe.com
BioRationality: FDA Removes Additional Testing for Interchangeable Status of Biosimilars

July 1st 2024

clinical efficacy trial preparation | Image credit: Cavan - stock.adobe.com
BioRationality—How to Promote Science to Secure Waiver of Comparative Efficacy Testing for Biosimilars

June 17th 2024

paroxysmal nocturnal hemoglobinuria | Image credit: Aryan - stock.adobe.com
EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris

June 15th 2024

breast cancer | Image credit: Romolo Tavani - stock.adobe.com
New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers

June 11th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.